Expression of β-Kotho, fibroblast growth factor receptor (FGFR)-1c and 2c, which bind FGF21, is decreased in the white adipose tissue of obese mice. The aim of the present study was to determine the role of FGFR2c in the development of obesity and diabetes in KKA mice. Treatment with mouse monoclonal FGFR2-IIIc antibody (0.5 mg kg) significantly suppressed body weight gain and epididymal white adipose tissue weight in individually housed KKA mice while having no effect on daily food intake. In addition, treatment with FGFR2-IIIc antibody significantly increased plasma-free fatty acid levels while having no effect on blood glucose or plasma FGF21 levels. Moreover, treatment with FGFR2-IIIc antibody had no significant effect on the expression of uncoupling protein-1, uncoupling protein-2 or peroxisome proliferator-activated receptor-γ coactivator 1α in the epididymal white adipose tissue. The treatment with FGFR2-IIIc antibody had no significant effects on daily food intake and body weight gain in individually housed KK mice. These findings suggest that FGFR2-IIIc upregulates the adiposity induced by social isolation in KKA mice, and that decreased expression and/or function of FGFR2c might be a compensatory response to enhanced adiposity. Inhibition of FGFR2-IIIc function might be a novel therapeutic approach for obesity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133360 | PMC |
| http://dx.doi.org/10.1038/nutd.2016.41 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New CRISPR/Cas9-based Fgfr2 mouse model of Crouzon syndrome exhibits skull and behavioral abnormalities.
J Mol Med (Berl)
October 2024
Craniomaxillofacial Surgery Department 1 of Plastic Surgery Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Article Synopsis
- - Crouzon syndrome (CS) is a craniofacial deformity caused by mutations in the FGFR2 gene, and traditional mouse models have had limitations like low efficiency and unstable traits.
- - This study used CRISPR/Cas9 to create a more accurate mouse model with a specific FGFR2 mutation that shows physical and behavioral traits similar to those seen in humans with CS, such as skull deformities and learning deficits.
- - The research confirmed the success of this gene-editing approach through various techniques, providing a valuable tool for understanding the disease and developing potential treatments.
PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2.
Yi Chuan
January 2024
Hengyang Medical College, University of South China, Hengyang 421001, China.
Article Synopsis
- - Hepatocellular carcinoma (HCC) is the leading form of liver cancer, known for its aggressive nature and complex mechanisms, particularly involving the RNA-binding protein PTBP1 which influences splicing events in cancer cells.
- - The study revealed that PTBP1 alters the expression of FGFR2 isoforms, reducing the tumor-suppressive FGFR2-IIIb while increasing the tumor-promoting FGFR2-IIIc in HCC cells, indicating a significant role in cancer progression.
- - Functional assays showed that the switch from FGFR2-IIIb to FGFR2-IIIc contributes to the aggressive nature of HCC by promoting epithelial-mesenchymal transformation (EMT) and activating key signaling pathways
Activated receptor tyrosine kinases in granulosa cells of ovulating follicles in mice.
Mol Reprod Dev
April 2018
Department of Animal Science, McGill University, Sainte-Anne-de-Bellevue, Quebec, Canada.
Successful ovulation requires the actions of gonadotropins along with those mediated by growth factors binding to their receptor tyrosine kinases (RTKs). There are several growth factors such as epidermal growth factor family ligands and interleukins that play a role during ovulation initiated by the preovulatory surge of luteinizing hormone (LH). The aim of this project was to analyze growth factor signaling pathways induced by LH in mouse granulosa cells.
View Article and Find Full Text PDF3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor.
Oncotarget
May 2017
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
We established two patient derived tumor cells (PDCs) from right and left pulmonary metastatic lesions respectively of a patient with giant cell tumor. At that time, patient-derived tumor cells from right and left surgical specimens were collected and cultured. High-throughput screening (HTS) for 24 drugs was conducted with a micropillar/microwell chip platform using giant cell tumor PDCs.
View Article and Find Full Text PDFTreatment with FGFR2-IIIc monoclonal antibody suppresses weight gain and adiposity in KKA mice.
Nutr Diabetes
November 2016
Department of Diabetes Technology, Tohoku University Graduate School of Biomedical Engineering, Sendai, Miyagi, Japan.
Expression of β-Kotho, fibroblast growth factor receptor (FGFR)-1c and 2c, which bind FGF21, is decreased in the white adipose tissue of obese mice. The aim of the present study was to determine the role of FGFR2c in the development of obesity and diabetes in KKA mice. Treatment with mouse monoclonal FGFR2-IIIc antibody (0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!